The historical rank and industry rank for Aquestive Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:
During the past 8 years, Aquestive Therapeutics's highest Price-to-Free-Cash-Flow Ratio was 46.70. The lowest was 8.51. And the median was 16.21.
AQST's Price-to-Free-Cash-Flow is not ranked *
in the Drug Manufacturers industry.
Industry Median: 22.61 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 55.50% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 36.90% per year.
During the past 8 years, Aquestive Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was 55.50% per year. The lowest was -85.90% per year. And the median was 22.60% per year.
Aquestive Therapeutics Price-to-Free-Cash-Flow Historical Data
The historical data trend for Aquestive Therapeutics's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aquestive Therapeutics's Price-to-Free-Cash-Flow
For the Drug Manufacturers - Specialty & Generic subindustry, Aquestive Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aquestive Therapeutics's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aquestive Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Aquestive Therapeutics's Price-to-Free-Cash-Flow falls into.
Aquestive Therapeutics's Share Price of today is $3.52. Aquestive Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.15.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Aquestive Therapeutics Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Aquestive Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Aquestive Therapeutics (Aquestive Therapeutics) Business Description
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AQST has been successfully added to your 